Loading
·
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
The quarterly reports for this company are not available yet. Please check back later.
In the mean time, check out some related stocks.